Gene or Genome
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Paving Way for Regulatory Filings
Gilead Sciences, Lenacapavir, HIV Prevention, Twice-Yearly PrEP, Regulatory Filings, PURPOSE 2 Trial
ITM Secures Exclusive Global License for Debiopharm’s CA IX-Targeted Theranostic Pair
ITM, Debiopharm, CA IX, Theranostic Pair, Radiopharmaceutical, Solid Tumors, Cancer Treatment
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Eyes 2025 Launch for HIV Prevention
Lenacapavir, HIV Prevention, Twice-Yearly Injection, Gilead Sciences, PrEP, PURPOSE 1 and 2 Trials, Regulatory Filings, 2025 Launch
Gilead Sciences and Genesis Therapeutics Collaborate on AI-Driven Small Molecule Drug Discovery
Gilead Sciences, Genesis Therapeutics, AI-driven drug discovery, small molecule therapies, strategic partnership, generative AI, drug development
Gilead and Genesis Therapeutics Partner on AI-Driven Small Molecule Therapies
AI drug discovery, Gilead Sciences, Genesis Therapeutics, small molecule therapies, generative AI, GEMS platform
AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval
TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)
Lilly and Haya Therapeutics Collaborate in $1 Billion Deal to Explore ‘Dark Genome’ for Obesity Treatments
Lilly, Haya Therapeutics, obesity, dark genome, RNA-based drug targets, biotech deal
Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Treatment
Fenebrutinib, Relapsing Multiple Sclerosis, BTK Inhibitor, Roche, Clinical Trials
Bayer’s Kerendia Demonstrates 16% Reduction in Cardiovascular Risk for Heart Failure Patients
Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER